amFAR | July 16, 2018Read the Publication
To achieve the benefits of innovative products, payers (Medicaid, Medicare, private insurers, the Ryan White HIV/AIDS Program, and others) must be engaged with clinicians, researchers, and consumers to consider how to deploy them.
In partnership with amfAR, the O’Neill Institute published a series of issue briefs. The briefs provide examination of critical policy issues that impact access, availability and acceptability of PrEP and long-acting agents, which are innovative forms of PrEP and HIV treatments that are under development and do not require daily pill taking. The series of briefs highlight the education and policy dialogues needed to prepare for innovative long-acting products transmission and reduce health care spending. Read all four reports in this series here.